Previous 10 | Next 10 |
Intercept Pharmaceuticals ( ICPT ) Q1 results : More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Intercept Pharma (NASDAQ: ICPT ): Q1 GAAP EPS of -$2.86 beats by $0.08 . More news on: Intercept Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide Ocaliva net sales of $72.7 million in the first quarter 2020, representing 40% growth over the prior year quarter Regulatory and commercial preparations on track for tentatively scheduled FDA advisory committee meeting and post-approval launch of OCA in liver fib...
Intercept Pharma (NASDAQ: ICPT ) is scheduled to announce Q1 earnings results on Monday, May 11th, before market open. The consensus EPS Estimate is -$2.87 (+5.3% Y/Y) and the consensus Revenue Estimate is $69.67M (+33.3% Y/Y). Over the last 2 years, ICPT has beaten EPS estimates 50%...
Summary NGM Biopharmaceuticals ( NGM ) is a business focused on large markets with diseases driven by clear mechanisms-of-action. Led by a strong management team with a de-risked pipeline, NGM is a unique business model. NGM is a stock to monitor with a lead asset pursuing the ~$20 billion...
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President an...
Over the past two-plus months, uncertainties tied to the coronavirus disease 2019 (COVID-19) have taken investors for quite the ride . Following a decline of 34% in the benchmark S&P 500 in a span of 33 calendar days, it's taken roughly five weeks for the broad-based index to regain close...
NEW YORK, April 27, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2020 financial result...
Despite a bit of a relief rally over the past two-plus weeks, it's still been a seven-week stretch that Wall Street and Main Street are never going to forget. After all, it's not often the stock market blows all-time records out of the water when it comes to the swiftness of a 20% or 30% decli...
Most major U.S. stock indices have rebounded sharply since hitting a multiyear low on March 23, 2020. The Dow Jones Industrial Average has gained a healthy 26% over the last two and a half weeks, while the S&P 500 has risen by nearly 23% during the same period. Despite this remarkable tu...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...